Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7P1J4)

Drug Name
Benralizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DM7P1J4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 5 receptor alpha (IL5RA) TTXH9AD IL5RA_HUMAN Modulator [3]
Interleukin-5 (IL5) TTPREZD IL5_HUMAN Modulator [4]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Lung tissue
The Studied Disease Chronic obstructive pulmonary disease [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-5 (IL5) DTT IL5 6.51E-01 -0.02 -0.11
Interleukin-5 (IL5) DTT IL5 1.71E-04 0.12 0.71
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
3 Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8.
4 Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma